If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Primary proposed target | HGF/c-Met signaling | Direct binding not confirmed |
| Research models | Rodent and cell studies | Preclinical only |
| Human clinical data | None published | Safety and efficacy unknown |
| Regulatory status | Unapproved research chemical | Status varies by country |
| Typical research purity | 95% or higher by HPLC | Depends on supplier and batch |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
== Production == The novel was partly inspired by Stephenson's involvement with the Clock of the Long Now project, to which he contributed three pages of sketches and notes. A separate compact disc, entitled IOLET: Music from the World of Anathem, containing eight experimental vocal compositions by David Stutz, was sold separately through CD Baby and the Long Now Foundation, with profits going to The Clock of the Long Now project. To create the world of Arbre, Stephenson constructs new vocabulary. In order to familiarize the reader with the new words, many of which are analogous to English, Latin or Greek words and ideas, a glossary is included at the end of the book. Each chapter begins with a definition of one of these words, which usually relates to the chapter in some way. In addition, the Orth language spoken by the characters was created by Jeremy Bornstein at the author's request, and has been documented. The word anathem was invented by Stephenson, based on the word anthem and the Greek word anathema. In the book, an anathem is a mathic ritual by which one is expelled from the mathic world.
=== Syrian transitional government (2024–present) === Following the fall of the Assad regime on 8 December 2024, the People's Assembly published a statement calling that day a "historic day in the lives of all Syrians", stating that it would work towards ensuring the upholding of the rule of law without discrimination. The statement included the new coat of arms of Syria, adorned with the flag of the Syrian opposition. On 11 December, the Ba'ath Party indefinitely halted all activities. The following day, the Syrian caretaker government suspended the assembly and constitution for a three-month transitional period. The People's Assembly was dissolved on 29 January 2025 when plans to establish an interim legislative council were announced by the Syrian transitional government. Following the adoption of the Constitutional Declaration of the Syrian Arab Republic, a provisional parliament called the "People's Assembly" was established to serve as the interim parliament during the five-year transition, overseeing the drafting of a new permanent constitution. The president selects one-third of the People's Assembly members, with the remaining two-thirds being elected through commissions supervised by a committee designated by the president. A presidential decree issued on 2 June 2025 established the Higher Committee for People's Assembly Elections. The 11-member committee is responsible for overseeing the formation of electoral sub-committees, which will elect two-thirds of the members of the People's Assembly.
Column C is the original assignment by Corey and Pauling. Column K is that of Koltun's patent. Column J is the color scheme used by the molecular visualizer Jmol. Column R is the scheme used by Rasmol; when two colors are shown, the second one is valid for versions 2.7.3 and later. Column P consists of the colors in the PubChem database managed by the United States National Institute of Health. All colors are approximate and may depend on the display hardware and viewing conditions.
Sources: en.wikipedia.org
=== Phase 2b clinical trial – ABSSSI === Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections The study started February 2014 and announced completed enrollment 19 August 2014. Overall, 215 patients were randomized to one of three dosing regimens of brilacidin (single dose 0.6 mg/kg; single-dose 0.8 mg/kg; 1.2 mg/kg over 3 days) or 7 days of once daily daptomycin. finding that a single dose brilacidin was comparable to 7 days of daptomycin. The primary endpoint was clinical success in the intent-to-treat population, defined as reduction of at least 20% in area of the ABSSSI lesion, relative to baseline, when observed 48–72 hours after the first dose of study drug, and no rescue antibiotics administered.
== Early life == Carrey was born in Newmarket, Ontario, Canada, to Kathleen (née Oram), a homemaker, and Percy Carrey, a musician and accountant. He was raised Catholic and had three older siblings. His mother was of Irish and Scottish descent, and his father was of French-Canadian ancestry; the family's original surname was Carré. At age eight, he began making faces before a mirror and discovered a talent for doing impressions. At age ten, Carrey wrote a letter to Carol Burnett of the Carol Burnett Show pointing out that he was already a master of impressions and should be considered for a role on the show; he was overjoyed when he received a form letter reply. A fan of Monty Python, whose television show Monty Python's Flying Circus aired in the 1970s, in 2014 Carrey appeared on Monty Python's Best Bits (Mostly) and recalled the effect on him of Ernest Scribbler (played by Michael Palin) laughing himself to death in "The Funniest Joke in the World" sketch. Radio Times states, "You'll see why immediately: Palin's performance is uncannily Carreyesque." Carrey spent his early years in the borough of Scarborough, Ontario, part of Metropolitan Toronto, where he attended Blessed Trinity Catholic Elementary School in North York. His family later moved to Burlington, Ontario, where they would spend eight years; Carrey attended Aldershot High School while there. Some time later, his family became homeless and lived together in a Volkswagen van while teenage Carrey and his brother spent months living in a tent in Charles Daley Park on the Lake Ontario shore in Lincoln, Ontario.
The Gallery of Botany is on the Allée the Buffon facing the centre of the garden, between the Gallery of Mineralogy and the Gallery of Palaeontology. At the corner is one of the two oldest trees in Paris, a Robinia pseudoacacia or black locust, planted in 1635 by Vespasien Robin, the royal gardener and botanist, from an earlier tree brought from America by his brother, also a botanist, in 1601. It is tied in age with another from the same source planted at the same time on the square of Saint-Julien-le-Pauvre. The Gallery was built in 1930–35 with a grant from the Rockefeller Foundation. Directly in front is a statue entitled "Science and Mystery" by Jean-Louis Schroeder, made in 1889. It depicts an old man pondering an egg, contemplating the enigma of which came first. The primary content of the gallery is the Herbier National, a collection representing 7.5 million plants collected since the founding of the museum. They are divided for study into Spermatophytes, plants which reproduce with seeds, and cryptogams, plants which reproduce with spores, such as algae, lichens and mushrooms. Many of the plants were collected by Jean Baptiste Christophore Fusée Aublet, the royal pharmacist and botanist in French Guiana. In 1775 he published his "Histoire des plantes de la Guiane Française" describing 576 genera and 1,241 species of neotropical plants, including more than 400 species that were new to science, at a time when only 20,000 plants had been described, The ground floor interior of the gallery has vestibules built in a combination of Art Deco and Neo-Egyptian styles.
Sources: en.wikipedia.org
Dihexa has been proposed to act through HGF and c-Met signaling. This pathway is linked to synapse formation and cellular growth. Direct binding and the precise molecular step remain uncertain.
No published human clinical trials are available for dihexa. Its safety and effectiveness in people are therefore unknown. Most available evidence comes from animal and cell studies.
Preclinical studies often measure dendritic spine density and synaptic protein levels. Behavioral tests include maze learning and avoidance tasks. These endpoints are indirect and do not establish clinical benefit.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.